2017
Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease
Zeiss CJ, Allore HG, Beck AP. Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease. PLOS ONE 2017, 12: e0171790. PMID: 28182759, PMCID: PMC5300282, DOI: 10.1371/journal.pone.0171790.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesClinical outcome measuresDisease-modifying interventionsNon-human primatesParkinson's diseaseOutcome measuresStudy designHuman studiesToxin-induced modelsHuman interventional studiesLongitudinal clinical outcomesPreclinical study designStudy design dataToxic protocolsClinical outcomesContemporary cohortNeuropathologic dataStudy design factorsInterventional studyMultiple time pointsPD phenotypeAnimal studiesIntervention characteristicsIntervention categoriesProgressive nature
2005
Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis
Toy EP, Bonafé N, Savlu A, Zeiss C, Zheng W, Flick M, Chambers SK. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. Clinical & Experimental Metastasis 2005, 22: 1-9. PMID: 16132573, DOI: 10.1007/s10585-005-0718-4.Peer-Reviewed Original ResearchConceptsBALB/cProto-oncogene expressionC-fms proto-oncogene expressionExpression groupAthymic BALB/cHuman breast cancer metastasisIntraperitoneal modelBreast cancer metastasisHuman breast carcinoma cellsBreast carcinoma cellsClinical outcomesClinical evidenceTumor sizeC-fmsIntrasplenic injectionPrimary tumorMetastatic spreadOral administrationRU 486SCID miceBreast carcinomaSCID animalsImmunodeficient miceIHC stainingNovel treatments